JP2023036899A5 - - Google Patents

Download PDF

Info

Publication number
JP2023036899A5
JP2023036899A5 JP2022211496A JP2022211496A JP2023036899A5 JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5 JP 2022211496 A JP2022211496 A JP 2022211496A JP 2022211496 A JP2022211496 A JP 2022211496A JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
antibody
pharmaceutical composition
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022211496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023036899A (ja
JP7606501B2 (ja
Filing date
Publication date
Priority claimed from JP2019542388A external-priority patent/JP7231549B2/ja
Application filed filed Critical
Publication of JP2023036899A publication Critical patent/JP2023036899A/ja
Publication of JP2023036899A5 publication Critical patent/JP2023036899A5/ja
Priority to JP2024218361A priority Critical patent/JP2025028191A/ja
Application granted granted Critical
Publication of JP7606501B2 publication Critical patent/JP7606501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022211496A 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 Active JP7606501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218361A JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
JP2019542388A JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019542388A Division JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218361A Division JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2023036899A JP2023036899A (ja) 2023-03-14
JP2023036899A5 true JP2023036899A5 (https=) 2023-10-03
JP7606501B2 JP7606501B2 (ja) 2024-12-25

Family

ID=63040120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019542388A Active JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2022211496A Active JP7606501B2 (ja) 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2024218361A Pending JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019542388A Active JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218361A Pending JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Country Status (7)

Country Link
US (2) US20220213206A1 (https=)
EP (1) EP3576793A4 (https=)
JP (3) JP7231549B2 (https=)
CN (1) CN110520158A (https=)
AU (2) AU2018215673B2 (https=)
CA (1) CA3049689A1 (https=)
WO (1) WO2018145075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900500TA (en) * 2016-07-22 2019-02-27 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD4324851T2 (ro) 2018-07-19 2025-12-31 Regeneron Pharma Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
KR20250099103A (ko) 2022-08-15 2025-07-01 다나-파버 캔서 인스티튜트 인크. Cldn4에 대한 항체 및 이의 사용 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
JP6636803B2 (ja) * 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
RS59340B1 (sr) * 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
AU2016227632A1 (en) 2015-03-05 2017-09-14 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
AU2016246695A1 (en) * 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
SG11201903693QA (en) * 2016-11-01 2019-05-30 Genmab Bv Polypeptide variants and uses thereof

Similar Documents

Publication Publication Date Title
JP2023036899A5 (https=)
JP2020505054A5 (https=)
KR101962483B1 (ko) 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
JP2018502050A5 (https=)
CA3095310A1 (en) Bi-functional proteins and construction thereof
RU2017142008A (ru) Новые полипептиды
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
JP2018504092A5 (https=)
JP2020501550A5 (https=)
US20260109748A1 (en) Modulation of dendritic cell lineages
JP2023159380A (ja) ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途
JP2024081718A5 (https=)
KR20230148169A (ko) 항-pd-l1 모노클로날 항체 및 인터루킨-15 (il-15), 인터루킨-15 수용체 15 알파 또는 인터루킨-2와의 융합 단백질
EP4149627A1 (en) Agonistic tumor necrosis factor receptor superfamily polypeptides
JP2026048706A (ja) 新規なｉｌ１０アゴニストおよびその使用方法
JP2019518713A5 (https=)
CA3017622A1 (en) Engineered trail for cancer therapy
CN114929745B (zh) Clec12a抗体片段序列和方法
WO2024017281A1 (zh) 多特异性抗体及其用途
JP2021531002A5 (https=)
JPWO2019176866A5 (https=)
RU2024116415A (ru) Композиции, содержащие улучшенные мультиспецифические связывающие агенты для иммунного ответа
JPWO2023089587A5 (https=)
JPWO2021133167A5 (https=)
NZ780860A (en) Bispecific antibody